Answers are grounded in this paper and cite their sources.
Demonstrates low CYP1A1 expression in human fetal adrenal and liver tissues, suggesting potential risks for fetal carcinogenesis.
Objective: To study the expression and inducibility in vitro of adrenal cytochrome P-450 (CYP) 1A1 implicated in precarcinogen and premutagen activation in human fetuses. Methods: CYP1A1 mRNA expression and CYP1A1 activity of fetal adrenals were studied and compared with those of fetal liver using the reverse transcriptase-polymerase chain reaction (RT-PCR) and 7-ethoxyresorufin O -deethylase (EROD) assay. Results: 3-methylcholanthrene (3MC, 25 mg/kg ip, qd×3), a selective inducer of CYP1A1, could enhance adrenal and liver EROD activities in vivo in adult rat. However, EROD activity was undetected in either adrenal microsomes or 3MC (0.5–2 µmol · L −1 for 24 h)-treated adrenal cells in vitro in human fetuses. Using RT-PCR method, the expression of CYP1A1 mRNA was detected in fetal adrenal and fetal liver tissues and the expressional percentage was 78% and 73%, respectively. Conclusion: Human fetal adrenals as well as fetal liver had the lower CYP1A1 expression and possessed the potential for risk of carcinogenesis during fetal development.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: